Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01103440 · ClinicalTrials.gov registry record · Phase 2
Aspirin Resistance and Percutaneous Coronary Intervention (PCI)
A Phase 2 study of Stable Angina, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT01103440: Completed Phase 2 study of Stable Angina, sponsored by Icahn School of Medicine at Mount Sinai.
NCT01103440 is a Phase 2 study of Stable Angina that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 36 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01103440, a Phase 2 study of Stable Angina, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to evaluate if aggressive antiplatelet therapy would reduce ischemic events in aspirin (ASA) resistant patients after percutaneous coronary intervention (PCI).
Primary Outcome
Number of participants with peri-procedural biomarker elevation defined as any elevation above baseline of CK-MB or Tn-I within 24 hours after completion of the procedure.
Conditions Studied
Interventions
- DRUG Intravenous Glycoprotein inhibitor + ASA, Clopidogrel
- DRUG Antiplatelet Therapy (ASA, Clopidogrel)
Study Locations (1)
New York
- Mount Sinai Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2007-04 |
| Est. Completion | 2009-06 |
| Phase | Phase 2 |
What the finished NCT01103440 record still lists
NCT01103440 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Stable Angina appearing as the primary indexed condition, and to 2 interventions - of which Intravenous Glycoprotein inhibitor + ASA, Clopidogrel is the first listed.
NCT01103440 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT01103440 about?
NCT01103440 is a clinical study titled "Aspirin Resistance and Percutaneous Coronary Intervention (PCI)". The objective of this study is to evaluate if aggressive antiplatelet therapy would reduce ischemic events in aspirin (ASA) resistant patients after percutaneous coronary intervention (PCI).
What is the current status of trial NCT01103440?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2007-04. Estimated completion is 2009-06.
What conditions does trial NCT01103440 study?
This clinical trial studies the following conditions: Stable Angina.
What interventions are being tested in trial NCT01103440?
The interventions under investigation include: Intravenous Glycoprotein inhibitor + ASA, Clopidogrel (DRUG), Antiplatelet Therapy (ASA, Clopidogrel) (DRUG).
Who is sponsoring clinical trial NCT01103440?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01103440 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stable Angina
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01103440's enrollment target sits among peer trials
36 1496th of 2000 higher than 477 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia